Latest Tempest Therapeutics News & Updates

See the latest news and media coverage for Tempest Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tempest Therapeutics

Clinical-stage biotechnology company developing in vivo CAR T therapies

tempesttx.com

Headquarters: Brisbane, United States
Company type: Public company
Number of employees: 10–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Tempest Therapeutics

In short: Tempest Therapeutics secured CAR-T licensing deals and raised over $7.5 million through private placements to fund its pipeline.

Company announcements

September 15 Tempest Therapeutics

Tempest secures exclusive option to license Senlang CD7 platform

The agreement complements Tempest's existing lipid nanoparticle delivery platform. The licensed candidate targets multiple myeloma and shows early clinical safety.

August 13 Tempest Therapeutics

Tempest Therapeutics reports second quarter 2026 financial results

The company advanced the TPST-4003 pipeline with a Senlang collaboration and raised $2 million via warrant inducement.

July 15 Tempest Therapeutics

Tempest Therapeutics announces next-gen in vivo CAR-T pipeline

Lead candidate TPST-4003 targets autoimmune diseases with first patient dosing expected in Q4 2026.

June 4 Tempest Therapeutics

Tempest Therapeutics appoints Drake Richey and John Yee to its board of directors

The appointments add expertise in corporate finance and therapeutic product development. They join effective June 4, 2026.

Media coverage

September 15 GlobeNewswire

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Tempest’s lead product candidate, ... to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective...

September 15 StreetInsider.com

Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang

Tempest Therapeutics (Nasdaq: TPST) has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. to potentially license Senlang's CD7-targeted lentiviral vector platform...

September 11 BioSpace

Tempest Therapeutics Announces Up to $7.5 Million Private Placement - BioSpace

Tempest's lead product candidate, ... to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective...

19 November 2025 Nasdaq

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BRISBANE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- In a transaction designed to both expand its pipeline and extend its runway, Tempest Therapeutics, Inc. (Nasdaq...

Never miss news about Tempest Therapeutics

Track Tempest Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tempest Therapeutics competitors & trending companies

Browse news for competitors to Tempest Therapeutics and other trending companies.